These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24447044)

  • 1. Serum microRNA levels in patients with Crohn's disease during induction therapy by infliximab.
    Fujioka S; Nakamichi I; Esaki M; Asano K; Matsumoto T; Kitazono T
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1207-14. PubMed ID: 24447044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNAs as biomarkers of adult Crohn's disease.
    Jensen MD; Andersen RF; Christensen H; Nathan T; Kjeldsen J; Madsen JS
    Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1038-44. PubMed ID: 26230660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W; Wang Y; Oddens BJ; Link R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics.
    Guglielmi G; Crucitta S; Bertani L; Ruglioni M; Baiano Svizzero G; Ceccarelli L; Del Re M; Danesi R; Costa F; Fogli S
    Inflamm Bowel Dis; 2024 Mar; 30(3):441-446. PubMed ID: 37696681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis.
    Coskun M; Bjerrum JT; Seidelin JB; Troelsen JT; Olsen J; Nielsen OH
    World J Gastroenterol; 2013 Jul; 19(27):4289-99. PubMed ID: 23885139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered microRNA expression in inflamed and non-inflamed terminal ileal mucosa of adult patients with active Crohn's disease.
    Guo Z; Wu R; Gong J; Zhu W; Li Y; Wang Z; Li N; Li J
    J Gastroenterol Hepatol; 2015 Jan; 30(1):109-16. PubMed ID: 24910152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
    Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
    Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical and endoscopic efficacy of step-up and top-down infliximab therapy in Crohn's disease].
    Xiao YL; Chen BL; He Y; Gao X; Huang MJ; Hu PJ; Chen MH
    Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):100-3. PubMed ID: 22490808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
    Nakahigashi M; Yamamoto T
    Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
    Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
    Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
    J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.